This week’s transactions span senior living, medical technology, clinical research, healthcare real estate, diagnostics, oncology and healthcare distribution.
Building specialist platforms
Some of the week’s transactions illustrate the appeal of building scaled platforms from specialist healthcare businesses.
Gilde Healthcare continued the build-out of its group of contract manufacturers for complex surgical instruments and implants, Surgical Precision Instruments (SPI), with the acquisition of Germany-based Bentec Endoscopy.
Gilde established SPI through the acquisitions of Chr. Diener in 2022 and Koscher & Würtz in 2023, followed by Rudischhauser in January 2026. Bentec is the latest addition, extending SPI’s capabilities into flexible and semi-flexible endoscopy instruments and broadening the range of minimally invasive applications it can serve.
Gilde intends to continue adding specialist manufacturers as the market consolidates.
Plastiflex Group’s acquisition of Italian company Sidam, which specialises in the supply of single-use medical devices for fluid management, adds capabilities to Plastiflex’s existing fluid management business while giving the group exposure to additional therapeutic areas.
The deal also expands Plastiflex’s manufacturing footprint and gives Sidam’s customers access to additional manufacturing capabilities across Asia and North America.
Consolidating the supply chain
Asker Healthcare Group has agreed to acquire Polish distributor Labo Clinic, following its acquisition of Norway-based Med Kjemi earlier in the week. Labo Clinic has a market-leading position in neurosurgical microscopes and supplies products and services across operating rooms, hospital pharmacies, chemotherapy, ENT and dental care. Med Kjemi, meanwhile, serves hospital laboratories and other healthcare customers in Norway.
These are relatively small businesses, but their strategic value increases when placed within Asker’s wider European network.
The model is well established: acquire specialist businesses with strong positions in individual markets, retain their local expertise and add them to a larger platform that can provide additional scale, resources and opportunities for cross-selling.
Separating real estate from operations
Platform building is not limited to manufacturing and distribution. It can also involve using specialist capital and operating expertise to expand into new markets.
Elevation Advisors’ European Senior Living (ESL) has agreed to acquire the real estate underlying a portfolio of nine German care homes and 40 assisted-living apartments, comprising 979 care beds and units.
The properties, located around Hamburg, Hanover, Dortmund and Cologne-Bonn, will be leased to Alloheim, Germany’s largest care home operator. Alloheim is also expanding its presence in the region through the acquisition of incumbent operator Integra Senior Citizens.
The transaction builds on Elevation’s European healthcare real estate strategy. The firm entered the European market in 2021 through a partnership with Clariane and has subsequently continued to expand its presence.
The structure also illustrates the separation of healthcare real estate from operations. Elevation can provide specialist real estate capital and investment expertise, while Alloheim operates the care businesses and gains additional scale in strategically important German regions.
Complementary technologies and capabilities
Other transactions this week bring complementary technologies and capabilities together.
Bruker has taken a majority investment in Dutch company Mimetas, whose organ-on-a-chip platforms and human tissue models are used in drug discovery and development.
Mimetas gives Bruker an entry into microphysiological systems and human physiology-relevant models, complementing its existing capabilities in proteomics, metabolomics, preclinical imaging and spatial biology.
Cureety’s acquisition of US-based Reimagine Care provides another example.
The transaction brings together Cureety’s therapy-specific monitoring and clinical triage capabilities with Reimagine Care’s AI-powered support and oncology-trained care teams. The combination creates an organisation that can extend precision oncology care beyond the clinic.
In both cases, the rationale is less about consolidation and more about combining capabilities to create something broader than either business could offer independently.
